Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in neoadjuvant and adjuvant NSCLC
NCT05383716Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Started Jul 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05383716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383716.